Aquestive Therapeutics (AQST) Stock: Buy, Sell, or Hold?
AQST - Aquestive Therapeutics, Inc. Common Stock
$4.55
0.11 (2.48%)
▲
5d:
-2.78%
30d:
-15.43%
90d:
+7.31%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When AQST Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AQST shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: AQST shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: AQST is currently trading at $4.55, which is considered oversold relative to its 30-day fair value range of $4.66 to $5.19.
Technical Outlook: Technically, AQST is in a strong uptrend. The price is currently testing key support at $4.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AQST scores 72/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $9.33 (+105.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AQST is in a strong uptrend. The price is currently testing key support at $4.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AQST scores 72/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $9.33 (+105.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.66 -
$5.19
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (72/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 105.1% below Wall St target ($9.33)
- CAUTION: Bottoming setup, but lagging the sector by 29% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$4.66 -
$5.19
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.43
Resistance Level
$5.11
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.98
Wall Street Target
$9.33
(+105.1%)
Revenue Growth (YoY)
38.1%
Profit Margin
-144.6%
Share & Embed Analysis
Last updated: October 03, 2026 7:00 AM ET
Data refreshes hourly during market hours. Next update: 8:00 AM
Data refreshes hourly during market hours. Next update: 8:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AQST showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
|
ALKS
Alkermes Plc |
BUY
15 analysts |
$57 | 62 BUY |
